DR. DANIEL WEINER - Corporate Board Profile

Simulations Plus, Inc.

Filing Date	Source Excerpt
2017-12-29	Dr. Daniel Weiner was appointed as a Director of the Company as of May 1, 2017. He has extensive industry knowledge and expertise. The Board has three committees: Audit Committee, Compensation Committee, and Nominating Committee. Dr. Daniel Weiner serves on all three committees. Director Compensation for Fiscal Year 2017: Dr. Daniel Weiner total compensation $24,570.
2018-12-31	DR. DANIEL WEINER was appointed as a Director of the Company as of May 1, 2017. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with emphasis on compartmental modeling. Dr. Weiner served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence assessment. Dr. Weiner has held senior management positions at companies such as Merrell Dow Pharmaceuticals; Statistical Consultants, Inc.; Syntex Development Research; Certara/Pharsight; Quintiles; and IVAX Research. Dr. Weiner is an Adjunct Associate Professor with Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina and is an Affiliate Professor of Pharmacometrics, Center for Translational Medicine in the School of Pharmacy at the University of Maryland. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software and is the co-author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. Weiner previously served as a Board member of DILIsym Services, Inc. (“DILIsym”), now a subsidiary of Simulations Plus, Inc. Dr. Weiner’s extensive industry knowledge, expertise, and experience makes him a qualified candidate for the Board.
2019-12-30	DR. DANIEL WEINER was appointed as a Director of the Company as of May 1, 2017. ... Director Compensation for Fiscal Year 2019: Dr. Daniel Weiner total compensation $193,867.
2020-12-29	DR. DANIEL WEINER was appointed as a Director of the Company as of May 1, 2017. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with emphasis on compartmental modeling. Dr. Weiner served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence assessment. Dr. Weiner has held senior management positions at companies such as Merrell Dow Pharmaceuticals; Statistical Consultants, Inc.; Syntex Development Research; Certara Inc.; Pharsight Corp.; Quintiles; and IVAX Research. Dr. Weiner is an Adjunct Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software and is the co-author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Dr. Weiner previously served as a Board member of DILIsym Services, Inc. (“DILIsym”), now a subsidiary of Simulations Plus, Inc. Dr. Weiner’s extensive industry knowledge, expertise, and experience makes him a qualified candidate for the Board.
2021-05-11	Dr. Daniel Weiner 2020 84,941 116,336 57,980 – 259,257 ...On July 17, 2020, the Board reviewed and approved the Nominating Committee’s recommendation to grant its non-employee directors non-qualified options to purchase common stock (“stock options”) taking into consideration market standards and the growth of the business. Options granted were; 5,000 each to Dr. Daniel Weiner...Stock options vest and become exercisable as follows: (i) no option shares will be vested prior to the grant date; and (ii) the balance of the option shares will vest annually on their anniversary date, 40% the first year, 30% the second and 30% the final year measured from the grant date, provided that there has not been a termination of service.
2021-12-17	DR. DANIEL WEINER has been a Director of the Company since May 1, 2017. ... The Board has three committees: Audit Committee, Compensation Committee, and Nominating & Corporate Governance Committee. ... Audit Committee members during fiscal year 2021: Dr. Daniel Weiner. ... Compensation Committee members during fiscal year 2021: Daniel Weiner (Chair). ... Nominating & Corporate Governance Committee members during fiscal year 2021: Dr. Daniel Weiner. ... Director Compensation for Fiscal Year 2021: Dr. Daniel Weiner total compensation $164,933.
2022-12-23	Dr. Daniel Weiner has been a director of the Company since May 1, 2017. ... Effective October 20, 2022, the Board appointed Dr. Daniel Weiner as the Board’s Lead Independent Director. ... Audit Committee members during fiscal year 2022: Dr. John K. Paglia (Chair), Dr. Lisa LaVange, Sharlene Evans. ... Compensation Committee members during fiscal year 2022: Dr. Daniel Weiner (Chair), Dr. Lisa LaVange, Sharlene Evans. ... Nominating & Corporate Governance Committee members during fiscal year 2022: Dr. Lisa LaVange (Chair), Dr. Daniel Weiner, Dr. John K. Paglia. ... Director Compensation Table: Dr. Daniel Weiner total compensation $142,554.
2023-12-22	Dr. Daniel Weiner has been a director of the Company since May 1, 2017. ... Dr. Weiner is an Adjunct Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina. ... We believe that Dr. Weiner’s extensive industry knowledge, expertise, and experience make him a qualified candidate for the Board.
2024-12-23	DR. DANIEL WEINER has been a director of the Company since May 1, 2017, served as Lead Independent Director of the Board from October 20, 2022 to December 17, 2024, and was appointed as Chairman of the Board on December 17, 2024. ... The Board has three committees: Audit Committee, Compensation Committee, and Nominating & Corporate Governance Committee. ... The table below shows all compensation awarded to, earned by or paid to our non-employee directors during the fiscal year 2024: Dr. Daniel Weiner 2024 90,000 120,071 210,071.